Experience with the use of hydroxychloroquine for the treatment of lupus erythematosus

Journal of Dermatology

Volumn 40, Issue 2, 2013, Pages 94-97

  Momose, Yoko ^a   Arai, Satoru ^a   Eto, Hikaru ^a   Kishimoto, Mitsumasa ^a   Okada, Masato ^a  

^a ST LUKE'S INTERNATIONAL HOSPITAL   (Japan)

Author keywords

Cutaneous Lupus Erythematosus Disease Area and Severity Index; discoid lupus erythematosus; hydroxychloroquine; systemic lupus erythematosus

Indexed keywords

ALPHA TOCOPHEROL; BERAPROST; CELECOXIB; CILOSTAZOL; CORTICOSTEROID; DIPHENYL SULFONE; DNA ANTIBODY; HYDROXYCHLOROQUINE; METHOTREXATE; PREDNISOLONE; SARPOGRELATE; SULFONE DERIVATIVE; TACROLIMUS; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; ADULT; ALOPECIA; ARTHRALGIA; ARTICLE; CLINICAL ARTICLE; CUTANEOUS LUPUS ERYTHEMATOSUS DISEASE AREA AND SEVERITY INDEX; DERMATOMYOSITIS; DISCOID LUPUS ERYTHEMATOSUS; DISEASE DURATION; DRUG APPROVAL; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TREATMENT FAILURE; ERYTHEMA; FEMALE; FOLLOW UP; HUMAN; JAPAN; LUPUS ERYTHEMATOSUS; LUPUS ERYTHEMATOSUS PROFUNDUS; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; PIGMENTATION; PROTEINURIA; RETINOPATHY; RETROSPECTIVE STUDY; SCREENING; SKIN LUPUS ERYTHEMATOSUS; SYSTEMIC LUPUS ERYTHEMATOSUS; TELANGIECTASIA;

ADOLESCENT; ADULT; ANTIRHEUMATIC AGENTS; FEMALE; HUMANS; HYDROXYCHLOROQUINE; JAPAN; LUPUS ERYTHEMATOSUS, CUTANEOUS; MIDDLE AGED; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84874116637     PISSN: 03852407     EISSN: 13468138     Source Type: Journal    
DOI: 10.1111/1346-8138.12005     Document Type: Article

References (9)

1. Kuhn A, Ruland V, Bonsmann G,. Cutaneous lupus erythematosus:update of therapeutic options Part I. J Am Acad Dermatol 2011; 65: e179-193.
2. Pons-Estel GJ, Alarcon GS, Gonzalez LA, et al,. Possible Protective Effect of Hydroxychloroquine on Delaying the Occurrence of Integument Damage in Lupus: LXXI, Date From a Multiethnic Cohort. Arthritis Care Res (Hoboken) 2010; 62: 393-400.
3. Wolfe F, Marmor MF,. Rates and predictors of hydroxychloroquine retinal toxicity in patients with rheumatoid arthritis and systemic lupus erythematosus. Arthritis Care Res (Hoboken) 2010; 62: 775-784.
4. Ruiz-Lrastorza G, Ramos-Casals M, Brito-Zeron P, et al,. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systemic review. Ann Rheum Dis 2010; 69: 20-28.
5. Levy RA, Vilela VS, Cataldo MJ, et al,. Hydroxychoroquine (HCQ) in lupus pregnancy: double-blind and placebo-controlled study. Lupus 2001; 10: 401-404.
6. Yokogawa N, Kato Y, Sugii S, et al,. Response to hydroxychloroquine in Japanese patients with systemic lupus erythematosus using the cutaneous lupus erythematosus disease area and severity index (CLASI). Mod Rheumatol 2012; 22: 249-255.
7. Ikeda T, Kanazawa N, Furukawa F,. Hydroxychloroquine administration for Japanease lupus erythematosus in Wakayama: a pilot study. J Dermatol 2012; 39: 531-535.
8. Albrecht J, Taylor L, Berlin JA, et al,. The CLASI(cutaneous lupus erythematosus disease area and severity index): an outcome instrument for cutaneous lupus erythematosus. J Invest Dermatol 2005; 125: 889-894.
9. Lesiak A, Narbutt J, Kobos J, et al,. Systematic administration of chloroquine in discois lupus erythematosus reduces skin lesions via inhibition of angiogenesis. Clin Exp Dermatol 2008; 34: 570-575.